Enfortumab Vedotin-ejfv provides a Nectin-4-targeting antibody-drug conjugate (ADC) for cancer and oncology research and specifically combines a Nectin-4-directed monoclonal antibody with monomethyl auristatin E (MMAE), supporting studies of targeted cytotoxicity, bladder cancer, and ADC mechanisms.
Key Features and Benefits
- Nectin-4-Targeting ADC: Combines a Nectin-4-directed monoclonal antibody with the cytotoxic MMAE payload specifically for targeted cancer research.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule-disrupting agent widely studied in ADC research.
- Nectin-4 Recognition: Supports investigation of Nectin-4 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable linker specifically designed to facilitate intracellular MMAE release following cellular uptake.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to Nectin-4-expressing cancer cells.
- Microtubule Disruption: MMAE inhibits microtubule polymerization, specifically supporting studies of cell-cycle arrest and ADC-mediated cytotoxicity.
- ADC Research Platform: Enables investigation of target engagement, cellular uptake, payload release, and ADC activity.
Applications
- Bladder Cancer Research: Supports investigation of Nectin-4-targeted ADC mechanisms in bladder cancer models.
- Urothelial Cancer Research: Useful for studying ADC targeting and cytotoxicity in Nectin-4-expressing urothelial carcinoma models.
- Nectin-4-Positive Cancer Research: Supports studies specifically involving tumors that express the Nectin-4 cell-surface protein.
- ADC Research: Especially useful for investigating antibody targeting, internalization, payload delivery, and cytotoxic activity.
- Targeted Cancer Research: Supports investigation of antibody-mediated delivery of MMAE to cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating Nectin-4-dependent binding, internalization, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of Nectin-4 targeting and MMAE-mediated microtubule disruption.
- Comparative ADC Research: Useful for comparing antibody targets, linkers, auristatin payloads, and ADC performance.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Enfortumab Vedotin-ejfv combines Nectin-4-directed antibody targeting with the microtubule-disrupting MMAE payload and specifically supports bladder cancer, urothelial cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
